These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23290598)

  • 1. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.
    Boxer AL; Knopman DS; Kaufer DI; Grossman M; Onyike C; Graf-Radford N; Mendez M; Kerwin D; Lerner A; Wu CK; Koestler M; Shapira J; Sullivan K; Klepac K; Lipowski K; Ullah J; Fields S; Kramer JH; Merrilees J; Neuhaus J; Mesulam MM; Miller BL
    Lancet Neurol; 2013 Feb; 12(2):149-56. PubMed ID: 23290598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration.
    Boxer AL; Lipton AM; Womack K; Merrilees J; Neuhaus J; Pavlic D; Gandhi A; Red D; Martin-Cook K; Svetlik D; Miller BL
    Alzheimer Dis Assoc Disord; 2009; 23(3):211-7. PubMed ID: 19812461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial.
    Li P; Quan W; Zhou YY; Wang Y; Zhang HH; Liu S
    Exp Ther Med; 2016 Jul; 12(1):492-498. PubMed ID: 27347084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.
    Costa ACS; Brandão AC; Boada R; Barrionuevo VL; Taylor HG; Roth E; Stasko MR; Johnson MW; Assir FF; Roberto MP; Salmona P; Abreu-Silveira G; Bederman I; Prendergast E; Hüls A; Abrishamcar S; Mustacchi Z; Scheidemantel T; Roizen NJ; Ruedrich S
    Lancet Neurol; 2022 Jan; 21(1):31-41. PubMed ID: 34942135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.
    Kulkarni J; Thomas N; Hudaib AR; Gavrilidis E; Grigg J; Tan R; Cheng J; Arnold A; Gurvich C
    CNS Drugs; 2018 Feb; 32(2):179-187. PubMed ID: 29549516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study.
    Noruzzadeh R; Modabbernia A; Aghamollaii V; Ghaffarpour M; Harirchian MH; Salahi S; Nikbakht N; Noruzi N; Tafakhori A
    Headache; 2016 Jan; 56(1):95-103. PubMed ID: 26638119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
    Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
    Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine in behavioral variant frontotemporal dementia: negative results.
    Vercelletto M; Boutoleau-Bretonnière C; Volteau C; Puel M; Auriacombe S; Sarazin M; Michel BF; Couratier P; Thomas-Antérion C; Verpillat P; Gabelle A; Golfier V; Cerato E; Lacomblez L;
    J Alzheimers Dis; 2011; 23(4):749-59. PubMed ID: 21157021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
    Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
    Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
    Gauthier S; Wirth Y; Möbius HJ
    Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 6-month, open-label study of memantine in patients with frontotemporal dementia.
    Diehl-Schmid J; Förstl H; Perneczky R; Pohl C; Kurz A
    Int J Geriatr Psychiatry; 2008 Jul; 23(7):754-9. PubMed ID: 18213609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up.
    Olivan-Blázquez B; Herrera-Mercadal P; Puebla-Guedea M; Pérez-Yus MC; Andrés E; Fayed N; López-Del-Hoyo Y; Magallon R; Roca M; Garcia-Campayo J
    Pain; 2014 Dec; 155(12):2517-2525. PubMed ID: 25218600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    Peyro Saint Paul L; Creveuil C; Heinzlef O; De Seze J; Vermersch P; Castelnovo G; Cabre P; Debouverie M; Brochet B; Dupuy B; Lebiez P; Sartori É; Clavelou P; Brassat D; Lebrun-Frenay C; Daplaud D; Pelletier J; Coman I; Hautecoeur P; Tourbah A; Defer G
    J Neurol Sci; 2016 Apr; 363():69-76. PubMed ID: 27000224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.